Lab Overview

The McDevitt lab is focused on the engineering of innovative technologies to translate the morphogenic potential of stem cells as models of development and disease, as well to develop cellular and molecular therapies aimed to treat degenerative diseases and traumatic injuries. Learn more about the research.

Since stem cells are promising for a number of applications, the emphasis of the McDevitt Lab is on the development of technology platforms to advance therapies that span multiple diseases.

Our technologies are applicable to a wide variety of diseases, including cardiovascular, orthopedic and neurological disorders. Specific diseases that we can apply our research to include treatments for diabetes, chronic wounds, aging, arthritis and other autoimmune disorders. The McDevitt lab's work also has other applications, including wound healing, irritable bowel syndrome, epilepsy and bone regeneration to name just a few. Click here for a complete list of research and disease applications.


  • Overview of Stem Cell Engineering
  • Todd was 1 of 6 panelists that toured Europe and Asia to do an international assessment of the Stem Cell Engineering field.


A researcher claims to have used the genome editing technique CRISPR-Cas9 to modify genes in two human embryos, which led to the birth of the first genetically edited babies.
Todd McDevitt and Gladstone scientists have a conversation with WIRED magazine.
New discoveries about how cells self-organize could help researchers create more authentic organ models for research or transplantation
McDevitt lab awarded a $3.5M grant from the NIH
Todd McDevitt and Bruce Conklin are launching a project to assess the safety of genome editing in human cells and tissues.
Scientists believe that the patterning of stem cell differentiation affects what kinds of cells will ultimately emerge from the differentiation process.